Division of Pediatric Dermatology

Saint Louis University School of Medicine's Division of Pediatric Dermatology offers comprehensive comprehensive medical, surgical and investigative services for children with all types of skin conditions.

Healthy Skin for Every Child

The Division of Pediatric Dermatology is committed to serving every child without financial barriers. It provides care for children with a wide range of skin conditions, including:

Inflammatory and immune-mediated diseases
Genetic and congenital disorders
Tumors and growths
Infections and blistering disorders
Diseases of the nails

The division provides both inpatient and outpatient services, as well as 24/7 remote consultation. Its pediatric dermatologists — who are among a select few serving the metro area — prioritize treating all children, regardless of ability to pay.

The division also offers lectures and didactic training for residents, medical students, allied health students and SSM Health Cardinal Glennon Children’s Hospital staff.

Pediatric Dermatology Research

Division researchers have participated in multi-center studies through the Pediatric Dermatology Research Alliance, the International Psoriasis Council, and universities across the nation. There are also collaborative opportunities for graduate students and both undergraduate and graduate medical students.

Clinical Trials

Phase 2, An Open-Label 5 year Extension Study to Evaluate the Safety of Etanercept in Pediatric Subjects with Plaque Psoriasis, Principal Investigator, Sponsor: Amgen
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis, Sponsor: Anacor
A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety, Efficacy, Systemic Exposure, and Pharmacodynamics of Calcipotriene Foam, 0.005%, Versus Vehicle Foam in Pediatric Subjects (Ages 2 to 11 Years) with Plaque Psoriasis (Site initiation 9/29/15), Sponsor: GSK-Stiefel
A Randomized, Double-Blind, Placebo-Controlled Study To Investigate The Efficacy and Safety Of Dupilumab Monotherapy In Patients 12 to 18 Years Of Age, With Moderate-To-Severe Atopic Dermatitis, Sponsor: Regeneron Pharmaceuticals
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris, Sponsor: Allergan, Inc.
A Phase 3 Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Subjects 6 to <12 Years of Age, Sponsor: Janssen Pharmaceutical
A Single Center, Investigator-Initiated Retrospective Review of Daily Subcutaneous Interferon-Gamma for Severe Inflammatory Skin Disease Complicated by Recurrent Eczema Herpeticum, Sponsor: Vidara

Collaborations

Multicenter Collaboration

PeDRA: The TREatment of severe Atopic dermatitis in children Taskforce (TREAT) U.S. and Canada Survey
PeDRA: Retrospective review of systemic therapy for atopic dermatitis in children
SUNY Downstate/Yale: Management of harlequin ichthyosis: consensus opinion
UT-Houston: Infantile hemangiomas: analysis of untreated lesions to establish early systemic treatment criteria
UCSD: Pediatric psoriasis disease and treatment: Effects on Concomitant NAFLD
International Psoriasis Council: Retrospective Chart Review of Systemic Treatments in Pediatric Psoriasis: An International Multicenter Study

Extramural Collaboration

Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By X-linked Hypohidrotic Ectodermal Dysplasia (XLHED): Intrafamilial Variation and Assessment of Skin Properties (NFED, University of Colorado via ICTS)
Systemic Therapies for Pediatric Atopic Dermatitis and Systemic Therapies for Pediatric Psoriasis (via PeDRA - Pediatric Dermatology Research Alliance - an independent multicenter consortium of clinical investigators)
Protocol Guidance for New Therapeutic Agents for Atopic Dermatitis in Children (via PeDRA; R-13 and WUSTL ICTS grants submitted)

Publications

Improved Management of Harlequin Ichthyosis With Advances in Neonatal Intensive Care. Glick JB, Craiglow BG, Choate KA, Kato H, Fleming RE, Siegfried E, Glick SA. Pediatrics. 2017 Jan;139(1). pii: e20161003. doi: 10.1542/peds.2016-1003. Epub 2016 Dec 20. PMID: 27999114
Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey. Totri CR, Eichenfield LF, Logan K, Proudfoot L, Schmitt J, Lara-Corrales I, Sugarman J, Tom W, Siegfried E, Cordoro K, Paller AS, Flohr C. J Am Acad Dermatol. 2017 Feb;76(2):281-285. doi: 10.1016/j.jaad.2016.09.021. Epub 2016 Nov 14. PMID: 27855965
Glick JB, Craiglow BG, Choate KA, Kato H, Fleming RE, Siegfried E, Glick SA. Improved Management of Harlequin Ichthyosis With Advances in Neonatal Intensive Care. Pediatrics. 2017 Jan;139(1). pii: e20161003. doi: 10.1542/peds.2016-1003. Epub 2016 Dec 20. PMID: 27999114
Siegfried EC, Jaworski JC, Eichenfield LF, Hebert AA, Paller AS. Optimizing Clinical Trials for Atopic Dermatitis in Children. J Invest Dermatol. 2017 Jun;137(6):1363-1364. doi: 10.1016/j.jid.2017.01.025. Epub 2017 Feb 9. PMID: 28189536
Kurta AO, Dai D, Armbrecht ES, Siegfried EC. Prescribing propranolol for infantile hemangioma: Assessment of dosing errors. J Am Acad Dermatol. 2017 May;76(5):999-1000. doi: 10.1016/j.jaad.2016.12.001. No abstract available. PMID: 28411779
Dhanda, M, Siegfried EC. Cost-Effective, Custom-Designed Wet Wrap Garments for Children: Experience at Cardinal Glennon Children’s Hospital. The Journal of Cutaneous Medicine. skin.dermsquared.com/skin
Serving as associate editor for the 5th edition of the Textbook of Pediatric Dermatology, Mosby

Abstracts

Chu MB, Siegfried EC, Wild AP, Reis M, Frieden IJ, Drolet B. “Iceberg” hemangioma: a segmental scalp lesion marking extensive multifocal extracutaneous involvement. Presented at the Annual Meeting of the Society for Investigative Dermatology, April 2016
Prindaville B, Horii KA, Siegfried EC, Brandling-Bennett H. Pediatric Dermatology Workforce in the United States. Presented at the World Congress for Pediatric Dermatology, July 5-9, 2017
Paller AS, Siegfried EC, Pariser DM, Rice, et al. Five-Year Open-Label Extension Study of Safety and Efficacy of Etanercept in Children and Adolescents With Moderate to Severe Plaque Psoriasis. Presented at the Annual Meeting of the American Academy of Dermatology, Washington DC; March 4-8, 2016
Darji K, Siegfried EC. Vitamin D deficiency and atopic dermatitis: consider disease, race, and body mass. Presented at the Annual Meeting of the Society for Investigative Dermatology Hebert AA, Siegfried EC, Baselga E, Chen L, Dang B. Infantile Hemangiomas: Analysis of Untreated Lesions to Establish Criteria for Early Systemic Treatment. Presented at the Annual Meeting of the American Academy of Dermatology, Washington DC; March 4-8, 2016
Paller AS, Bronckers M, Seyger M, Kiguradze T, West T, Day J, Groenewoud M, PeDRA Psoriasis Investigator Group (W. Tom, M. Tollefson, I. Lara-Corrales, N. Celano, R.A. Vleugels, E. Siegfried, M. Hogeling, L. Belazarian, A. Winkler, K. Holland, and K. Cordoro) and the European Working Group on Pediatric Psoriasis. Systemic Agents in Pediatric Psoriasis: International Study of Characteristics, Comorbidities, and Adverse Events. Presented at the Annual Meeting of the Society for Pediatric Dermatology, July 2016

Explore All Dermatology Research